These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
678 related articles for article (PubMed ID: 25483637)
1. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa. Sawa T; Ito E; Nguyen VH; Haight M Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637 [TBL] [Abstract][Full Text] [Related]
2. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice. Moriyama K; Wiener-Kronish JP; Sawa T Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258 [TBL] [Abstract][Full Text] [Related]
3. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia. Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708 [TBL] [Abstract][Full Text] [Related]
4. PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury. Wang Q; Li H; Zhou J; Zhong M; Zhu D; Feng N; Liu F; Bai C; Song Y Respir Physiol Neurobiol; 2014 Mar; 193():21-8. PubMed ID: 24418353 [TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. Frank DW; Vallis A; Wiener-Kronish JP; Roy-Burman A; Spack EG; Mullaney BP; Megdoud M; Marks JD; Fritz R; Sawa T J Infect Dis; 2002 Jul; 186(1):64-73. PubMed ID: 12089663 [TBL] [Abstract][Full Text] [Related]
6. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa. Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613 [TBL] [Abstract][Full Text] [Related]
11. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Imamura Y; Yanagihara K; Fukuda Y; Kaneko Y; Seki M; Izumikawa K; Miyazaki Y; Hirakata Y; Sawa T; Wiener-Kronish JP; Kohno S Eur Respir J; 2007 May; 29(5):965-8. PubMed ID: 17301098 [TBL] [Abstract][Full Text] [Related]
12. Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models. Ranjbar M; Behrouz B; Norouzi F; Mousavi Gargari SL Mol Immunol; 2019 Dec; 116():98-105. PubMed ID: 31634816 [TBL] [Abstract][Full Text] [Related]
13. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Baer M; Sawa T; Flynn P; Luehrsen K; Martinez D; Wiener-Kronish JP; Yarranton G; Bebbington C Infect Immun; 2009 Mar; 77(3):1083-90. PubMed ID: 19103766 [TBL] [Abstract][Full Text] [Related]
14. A Live Aguilera-Herce J; García-Quintanilla M; Romero-Flores R; McConnell MJ; Ramos-Morales F mSphere; 2019 Apr; 4(2):. PubMed ID: 30996108 [No Abstract] [Full Text] [Related]
15. PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Song Y; Baer M; Srinivasan R; Lima J; Yarranton G; Bebbington C; Lynch SV Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1837-45. PubMed ID: 22187351 [TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. François B; Luyt CE; Dugard A; Wolff M; Diehl JL; Jaber S; Forel JM; Garot D; Kipnis E; Mebazaa A; Misset B; Andremont A; Ploy MC; Jacobs A; Yarranton G; Pearce T; Fagon JY; Chastre J Crit Care Med; 2012 Aug; 40(8):2320-6. PubMed ID: 22622405 [TBL] [Abstract][Full Text] [Related]
17. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Neely AN; Holder IA; Wiener-Kronish JP; Sawa T Burns; 2005 Mar; 31(2):153-8. PubMed ID: 15683685 [TBL] [Abstract][Full Text] [Related]
18. Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa. Golpasha ID; Mousavi SF; Owlia P; Siadat SD; Irani S Bosn J Basic Med Sci; 2015 May; 15(2):15-24. PubMed ID: 26042508 [TBL] [Abstract][Full Text] [Related]